Relmada Therapeutics (RLMD)

P/B ratio as of July 2026 : 2.50

According to Relmada Therapeutics's latest financial reports the company has a price-to-book ratio of 0.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Relmada Therapeutics - P/B ratio (from 2014 to 2026)

P/B ratio by year

Year	P/B ratio	Change
2026-12-31	N/A	-100%
2025-12-31	3.70	1038.6%
2024-12-31	0.3253	-77.71%
2023-12-31	1.46	95.17%
2022-12-31	0.7480	-75.07%
2021-12-31	3.00	-39.51%
2020-12-31	4.96	1.78%
2019-12-31	4.87	-79.57%
2018-12-31	23.9	82.88%
2017-12-31	13.0	364.91%
2016-12-31	2.81	10.05%
2015-12-31	2.55	-92.96%
2014-12-31	36.2
2013-12-31	N/A
2012-12-31	N/A

P/B ratio for similar companies or competitors

Company	P/B ratio	P/B ratio differencediff.	Country
Cytokinetics CYTK	-13.5	-639.13%	🇺🇸 USA
Taro Pharmaceutical TARO	0.9078	-63.63%	🇮🇱 Israel

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Relmada Therapeutics (RLMD) - P/B ratio